Monsanto’s latest herbicide-resistant GMO soybeans face regulatory delays at home, abroad

Screen Shot at PM
Image: United Soybean Board/Flickr

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Soybean growers looking to try out new weapons in their fight against weeds will have to wait a while longer.

. . . .

Monsanto’s Roundup Ready 2 Xtend soybeans, which are resistant to both glyphosate and dicamba, are still on a regulatory hold, at least a year after the company expected. While the beans have been approved for planting this year, the EPA has held back on allowing over-the-top application of dicamba on the plants, nullifying part of the benefit.

In addition, the European Union has not approved import of the beans.

Other products are also on a waiting list in some form or other. They include Dow’s Enlist Duo soybeans, which are resistant to both glyphosate and 2,4-D.

While the chemistry has been approved in the United States, China has not granted import approval.

. . . .

Dow expects a full launch for 2017, though the company acknowledges there is no guarantee on whether the beans will be allowed into Europe. Meanwhile, they are being grown for seed this year . . .

Read full, original post: Some GMO trait launches face regulatory delays

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

vax-misinformation-main
Facts & Fallacies Podcast: Limit free speech to blunt social media misinfo?
Picture1
The FDA couldn’t find a vaccine safety crisis, so it buried its own research
ChatGPT-Image-May-7-2026-01_23_27-PM-2
Viewpoint: Will AI democratize personalized cancer treatment or fuel medical misinformation?
ChatGPT-Image-Apr-16-2026-02_56_53-PM
Financial incentives, over diagnosis, and weak oversight: Autism claims are driving up Medicare costs
ChatGPT-Image-May-12-2026-11_27_01-AM-2
AI likely to improve health care, research shows—but not for blacks and ethnic minorities
modi visit sikkim
Viewpoint: Indian PM wants farmers to switch to 50% organic. It would take at least 10 years, likely won’t work, and isn’t more sustainable
Screenshot-2026-04-22-at-12.21.32-PM
Viewpoint: Why the retracted Monsanto glyphosate study doesn’t change the science—the world’s most popular herbicide is safe 
ChatGPT-Image-May-20-2026-04_53_21-PM-2
Viewpoint: Doctors can fight health misinformation — if hospitals let them
newborn infant baby mother
Sharp rise in number of parents refusing newborn vitamin K shots, putting babies at 81-fold higher risk of severe bleeding
ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-05-18-at-3.04.37-PM-2
Social media’s health advice red flags
Screenshot-2026-05-19-at-11.23.34-AM
West-originated vaccine disinformation sparks murders of health care workers across Africa
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.